Mitochondrial DNA copy number and trimethylamine levels in the blood: New insights on cardiovascular disease biomarkers.
Laura BordoniIrene PetracciIwona Pelikant-MaleckaAdriana RadulskaPiangerelli MarcoJoanna J SamulakLukasz LewickiLeszek KalinowskiRosita GabbianelliRobert Antoni OlekPublished in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2021)
Among cardiovascular disease (CVD) biomarkers, the mitochondrial DNA copy number (mtDNAcn) is a promising candidate. A growing attention has been also dedicated to trimethylamine-N-oxide (TMAO), an oxidative derivative of the gut metabolite trimethylamine (TMA). With the aim to identify biomarkers predictive of CVD, we investigated TMA, TMAO, and mtDNAcn in a population of 389 coronary artery disease (CAD) patients and 151 healthy controls, in association with established risk factors for CVD (sex, age, hypertension, smoking, diabetes, glomerular filtration rate [GFR]) and troponin, an established marker of CAD. MtDNAcn was significantly lower in CAD patients; it correlates with GFR and TMA, but not with TMAO. A biomarker including mtDNAcn, sex, and hypertension (but neither TMA nor TMAO) emerged as a good predictor of CAD. Our findings support the mtDNAcn as a promising plastic biomarker, useful to monitor the exposure to risk factors and the efficacy of preventive interventions for a personalized CAD risk reduction.
Keyphrases
- mitochondrial dna
- copy number
- coronary artery disease
- cardiovascular disease
- end stage renal disease
- genome wide
- chronic kidney disease
- newly diagnosed
- ejection fraction
- type diabetes
- risk factors
- blood pressure
- dna methylation
- cardiovascular events
- patient reported outcomes
- gene expression
- adipose tissue
- cardiovascular risk factors
- left ventricular
- glycemic control
- atomic force microscopy
- single molecule